Form 4: Enliven CEO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics President and CEO Samuel Kintz sold 3,700 shares of common stock for $20.0615 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved 3,700 shares of Enliven Therapeutics common stock.
• The shares were sold at a weighted average price of $20.0615 per share.
• The total value of the transaction was approximately $74,227.55.
• The sale was executed on September 26, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kintz on November 15, 2024.
• Following this transaction, Mr. Kintz directly beneficially owns 915,392 shares, held indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new company-specific information. The transaction size is relatively small compared to the CEO's total beneficial ownership, leading to a neutral sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information and suggests a planned diversification or liquidity event rather than a reaction to negative company-specific news.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the relatively small size and the 10b5-1 plan mitigate this perception.

Future Outlook

N/A

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The 915,392 shares beneficially owned by Samuel Kintz are held indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee, indicating an indirect beneficial ownership structure.

Stakeholder Impact

• Shareholders: Minor impact. A planned insider sale of this size is generally not a significant signal of future performance, but some investors may view any insider selling with caution.
• Employees, Customers, Suppliers, Creditors: No direct impact from this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider sale by the CEO under a Rule 10b5-1 trading plan. Such transactions are typically for personal financial planning or diversification and do not usually signal a change in the company's fundamental outlook or warrant a change in investment thesis based solely on this information. The transaction size is not substantial enough to suggest a significant shift in insider sentiment.

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, director, common stock